Microtransplantation Outcomes for Older AML Patients, 2008-2021 Single-Center Study

Between April 2008 and June 2021, a single-center study of 29 patients aged 60 and over with newly diagnosed acute myeloid leukemia (AML) received microtransplantation therapy. The dataset includes endpoints such as complete remission rates, overall survival, leukemia-free survival, and safety outcomes, with a median follow-up of 148.5 months. Author Juan Liu published the data under a CC-BY-4.0 license.

Use Cases

• Modeling overall survival (OS) and leukemia-free survival (LFS) based on patient age cohorts (60-70 vs. >70 years).
• Analyzing the association between treatment course count (>3 courses) and improved patient outcomes.
• Investigating relapse incidence and non-relapse mortality (NRM) using competing risk analysis methods.
• Exploring transcriptomic gene expression profiles linked to long-term survival in a patient subset.

Strengths

• Long-term follow-up with a median of 148.5 months (over 12 years).
• Includes detailed clinical endpoints for 29 patients, such as an 86.2% complete remission rate.
• Data covers a specific 13-year time range (2008-2021) for a defined patient population.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study with 29 patients, limiting generalizability.

Provenance

Source

figshare, author Juan Liu.

Collection Method

Single-center clinical study data collection.

Time Range

April 2008 to June 2021.

Freshness

Last updated 2026-03-18 07:39:48; freshness should be verified.

Geography

Location of the single center is unknown.